Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of IMVT-1402 in generalized myasthenia gravis
2024-515979-35-00Phase 3Authorised
- Sponsor
- Immunovant, Inc.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing IMVT-1402 with Placebo (2 arms). Primary endpoint: Change from baseline in MG-ADL score for antibody-positive participants. Planned start Nov 2025; status: authorised.
02
Drugs
IMVT-1402
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2024-515979-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515979-35-00.